Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions

Sorber, Laure; Zwaenepoel, Karen; Jacobs, Julie; Winne, Koen De; Casteren, Kaat Van; Augustus, Elien; Lardon, Filip; Prenen, Hans; Peeters, Marc; Meerbeeck, Jan P. van; Roeyen, Geert; Rolfo, Christian; Pauwels, Patrick

doi:10.1007/s40291-019-00442-w

Cited by 28 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Roche tubes are not desirable in experiments that require larger amounts of DNA, as we have observed a decrease in cfDNA concentration over time. In studies where both cfRNA and cfDNA are being investigated, a preservation tube with the best overall performance should be selected [ 30 ]. For example, DNA Streck tubes are incompatible with the analysis of extracellular RNA [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome

et al. 2020

View full text Add to dashboard Cite

The methylation pattern of cfDNA, isolated from liquid biopsies, is gaining substantial interest for diagnosis and monitoring of diseases. We have evaluated the impact of type of blood collection tube and time delay between blood draw and plasma preparation on bisulphite-based cfDNA methylation profiling. Fifteen tubes of blood were drawn from three healthy volunteer subjects (BD Vacutainer K2E EDTA spray tubes, Streck Cell-Free DNA BCT tubes, PAXgene Blood ccfDNA tubes, Roche Cell-Free DNA Collection tubes and Biomatrica LBgard blood tubes in triplicate). Samples were either immediately processed or stored at room temperature for 24 or 72 hours before plasma preparation. DNA fragment size was evaluated by capillary electrophoresis. Reduced representation bisulphite sequencing was performed on the cell-free DNA isolated from these plasma samples. We evaluated the impact of blood tube and time delay on several quality control metrics. All preservation tubes performed similar on the quality metrics that were evaluated. Furthermore, a considerable increase in cfDNA concentration and the fraction of it derived from NK cells was observed after a 72-hour time delay in EDTA tubes. The methylation pattern of cfDNA is robust and reproducible in between the different preservation tubes. EDTA tubes processed as soon as possible, preferably within 24 hours, are the most cost effective. If immediate processing is not possible, preservation tubes are valid alternatives.

show abstract

Section: Discussionmentioning

confidence: 99%

Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Thus EDTA tubes require expedient sample processing within 6 hours, compared with ≥48 hours with cell-stabilizing tubes. 50,51 Comprehensive data do not exist to inform performing draws from other sites (eg, from ports, arteries, or central veins) or other specimen handling variables (eg, tube inversions, draw order, or fill levels).…”

Section: Preanalytical Variablesmentioning

confidence: 99%

“…Cell‐stabilizing tubes contain reagents that stabilize cell membranes, decreasing cell lysis and release of cellular genomic DNA from leukocytes and other cells into plasma. Thus EDTA tubes require expedient sample processing within 6 hours, compared with ≥48 hours with cell‐stabilizing tubes 50,51 . Comprehensive data do not exist to inform performing draws from other sites (eg, from ports, arteries, or central veins) or other specimen handling variables (eg, tube inversions, draw order, or fill levels).…”

Section: Summary Of the 2018 American Society Of Clinical Oncology/comentioning

confidence: 99%

Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions

Cheng

Pectasides

Hanna

et al. 2020

CA A Cancer J Clinicians

118

View full text Add to dashboard Cite

The application of genomic profiling assays using plasma circulating tumor DNA (ctDNA) is rapidly evolving in the management of patients with advanced solid tumors. Diverse plasma ctDNA technologies in both commercial and academic laboratories are in routine or emerging use. The increasing integration of such testing to inform treatment decision making by oncology clinicians has complexities and challenges but holds significant potential to substantially improve patient outcomes. In this review, the authors discuss the current role of plasma ctDNA assays in oncology care and provide an overview of ongoing research that may inform real‐world clinical applications in the near future.

show abstract

“…In this context, different options can be considered: (i) increasing the volume of the blood sample taken from the patient to obtain a higher quantity of nucleic acid after extraction. However, it does not seem possible to get more than 20 mL from patients with metastatic lung cancer (the average volume is 10 mL of blood in daily practice); (ii) optimize the pre-analytical steps by using an efficient buffer that limits degradation of leucocytes and thus the release of germinal DNA from these cells into the blood; (iii) reduce as much as possible the time between blood puncture and the centrifugation steps and (iv) use some new reagents that increase nucleic acid extraction from plasma and thus optimize the ratio between the available plasmatic volume and the amount of extracted nucleic acid [ 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 ].…”

Section: Ngs With Blood At Diagnosis Of Advanced Non-small Cell Lung Carcinoma: How To Optimize?mentioning

confidence: 99%

Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients

Hofman

2021

Cancers

View full text Add to dashboard Cite

Recently, the liquid biopsy (LB), a non-invasive and easy to repeat approach, has started to compete with the tissue biopsy (TB) for detection of targets for administration of therapeutic strategies for patients with advanced stages of lung cancer at tumor progression. A LB at diagnosis of late stage non-small cell lung carcinoma (NSCLC) is also being performed. It may be asked if a LB can be complementary (according to the clinical presentation or systematics) or even an alternative to a TB for treatment-naïve advanced NSCLC patients. Nucleic acid analysis with a TB by next-generation sequencing (NGS) is gradually replacing targeted sequencing methods for assessment of genomic alterations in lung cancer patients with tumor progression, but also at baseline. However, LB is still not often used in daily practice for NGS. This review addresses different aspects relating to the use of LB for NGS at diagnosis in advanced NSCLC, including its advantages and limitations.

show abstract

Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions

Cited by 28 publications

References 33 publications

Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome

Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome

Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions

Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients

Contact Info

Product

Resources

About